Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.61 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.60 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.60 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.60 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30368222 | 1.00 | ALDH1A1 (0.66) | ALDH1A1MAPTKMT2AMEN1MAPK14 | |
| SCHEMBL10533351 | 0.94 | ALDH1A1 (0.77) | ALDH1A1MAPTKMT2AMEN1MAPK14 | |
| SCHEMBL26274509 | 0.86 | ALDH1A1 (0.61) | ALDH1A1MAPTKMT2AMEN1MAPK14 | |
| SCHEMBL26274009 | 0.86 | LMNA (0.57) | ALDH1A1MAPTKMT2AMEN1MAPK14 | |
| SCHEMBL30606801 | 0.85 | MAPT (0.87) | ALDH1A1MAPTKMT2AMEN1PDK1 | |
| SCHEMBL29580531 | 0.85 | MAPT (0.87) | ALDH1A1MAPTKMT2AMEN1PDK1 | |
| SCHEMBL26273989 | 0.85 | LMNA (0.54) | ALDH1A1MAPTKMT2AMEN1MAPK14 | |
| SCHEMBL26274530 | 0.84 | ALDH1A1 (0.49) | ALDH1A1MAPTKMT2AMEN1MAPK14 | |
| SCHEMBL1040883 | 0.84 | ALDH1A1 (0.59) | ALDH1A1MAPTKMT2AMEN1HSD17B10 | |
| SCHEMBL6464794 | 0.84 | MAPT (0.68) | ALDH1A1MAPTKMT2AMEN1PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1041198-C | Method for synthesizing 5-[1-hydroxy-2-(isopropylamino)ethyl] aminobenzonitrile | UNIV BEIJING AGRICULT (CN) | 1998-12-16 | — | — | CN | claimed |
| CN-1120535-A | Method for synthesizing 5-[1-hydroxy-2-(isopropylamino)ethyl] aminobenzonitrile | UNIV BEIJING AGRICULT (CN) | 1996-04-17 | — | — | CN | claimed |
| WO-2023226965-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-11-30 | — | — | WO | disclosed |
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-3838903-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2021-06-23 | — | — | EP | disclosed |
| WO-2021038426-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-03-04 | — | — | WO | disclosed |
| EP-3466953-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2021-02-03 | — | — | EP | disclosed |
| EP-2343298-B9 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2020-05-06 | — | — | EP | disclosed |
| US-10398699-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3466953-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2019-04-10 | — | — | EP | disclosed |
| CN-108727307-A | Compound and its application method | 安吉奥斯医药品有限公司 | 2018-11-02 | — | — | CN | disclosed |
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-03-06 | — | — | US | disclosed |
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| CN-1041198-C | Method for synthesizing 5-[1-hydroxy-2-(isopropylamino)ethyl] aminobenzonitrile | UNIV BEIJING AGRICULT (CN) | 1998-12-16 | — | — | CN | disclosed |
| CN-1120535-A | Method for synthesizing 5-[1-hydroxy-2-(isopropylamino)ethyl] aminobenzonitrile | UNIV BEIJING AGRICULT (CN) | 1996-04-17 | — | — | CN | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4632983-A | Pyridone dyes containing a oxydiazone substituent | BASF AKTIENGESELLSCHAFT (DE) | 1986-12-30 | — | — | US | disclosed |
| EP-0111236-B1 | PYRIDONE DYESTUFFS | BASF Aktiengesellschaft (DE) | 1986-07-30 | — | — | EP | disclosed |
| EP-0111236-A1 | Pyridone dyestuffs | BASF Aktiengesellschaft (DE) | 1984-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10398699-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | JAK3, JAK1, JAK2 | ALDH1A1 3413/4885MAPT 3547/4885KMT2A 780/4885 |
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | F2, F12, F3 | ALDH1A1 956/4885MAPT 3321/4885KMT2A 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.